Dr. Reddy’s Laboratories Ltd with ticker code (RDY) have now 3 analysts in total covering the stock. The consensus rating is pointing to ‘Strong_Buy’. The target price High/Low ranges between 67 and 60.6 and has a mean target at $62.87. Given that the stocks previous close was at $57.95 this now indicates there is a potential upside of 8.5%. The 50 day MA is $54.63 while the 200 day moving average is $53.86. The total market capitalization for the company now stands at $9,767m. Find out more information at: https://www.drreddys.com
The potential market cap would be $10,596m based on the market consensus.
Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy’s Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 21.78, revenue per share of 1429.43 and a 9.49% return on assets.
